Published:
Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
DALLAS, March 10 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.
(OTC Bulletin Board: ACCP) announced today that its management team has
scheduled a conference call for March 13, 2008 at 10:00 a.m. ET to update the
financial community about the status of its clinical trial programs as well as
its business opportunities.
Interested parties may participate in the call by dialing (877) 407-8293;
callers outside the U.S. may participate by dialing (201) 689-8349 about 5-10
minutes prior to 10:00 a.m. ET. The conference call will also be available on
replay starting at 12:00 noon ET on March 13, 2008, and ending on April 13,
2008. For the replay, U.S. participants please dial (877) 660-6853 (replay
account # 294, replay conference #278416). The access number for the replay
for callers outside the U.S. is (201) 612-7415 (replay account # 294, replay
conference # 278416).
About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that
develops and commercializes propriety products for the treatment and
supportive care of cancer patients. Access' products include ProLindac(TM),
currently in Phase 2 clinical testing of patients with ovarian cancer, and
MuGard(TM) for the management of patients with mucositis. The company also has
other advanced drug delivery technologies including Cobalamin(TM) -- mediated
targeted delivery and oral drug delivery, its proprietary nanopolymer delivery
technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a
humanized monoclonal antibody which acts as an anti-angiogenesis factor and is
targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated
in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a
chemotherapeutic agent that combines multiple modes of action to overcome drug
resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor
and differentiating agent currently a Phase 2 clinical candidate. For
additional information on Access Pharmaceuticals, please visit our website at
http://www.accesspharma.com.
This press release contains certain statements that are forward-looking
within the meaning of Section 27a of the Securities Act of 1933, as amended,
and that involve risks and uncertainties. These statements include those
relating to: our ability to close the financing transaction, early results
from our clinical trial, Access' plans to continue and initiate clinical
trials, the value of its products in the market, its ability to achieve
clinical and commercial success and its ability to successfully develop
marketed products. These statements are subject to numerous risks, including
but not limited Access' need to obtain additional financing in order to
continue the clinical trial and operations and to the risks detailed in
Access' Annual Reports on Form 10-KSB and other reports filed by Access with
the Securities and Exchange Commission.
SOURCE Access Pharmaceuticals, Inc.
Copyright © 2009, PRNewswire
Copyright © 2009, NewsBlaze,
Daily NewsTags: ,HEA,MTC,OTC,CCA,TRI,TX-Access-Pharmaceuti
Search News
Daily News
